Sugi Predict

Sugi Predict / Compounds / SCHEMBL99690

SCHEMBL99690

SCHEMBL99690

Brc1ccnc2[nH]ccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PRKCI P41743 4/20 1.00
▸ AXL P30530 2/20 0.59
▸ IKBKB O14920 3/20 0.52
▸ CHUK O15111 3/20 0.52
▸ AURKB Q96GD4 3/20 0.52
▸ IGF1R P08069 2/20 0.52
▸ DYRK1B Q9Y463 2/20 0.52
▸ DAPK3 O43293 1/20 0.52
▸ JAK2 O60674 1/20 0.52
▸ PRKD3 O94806 1/20 0.52
▸ MAP4K4 O95819 1/20 0.52
▸ PAK4 O96013 1/20 0.52
▸ CSF1R P07333 1/20 0.52
▸ RET P07949 1/20 0.52
▸ FGFR1 P11362 1/20 0.52
▸ PRKACA P17612 1/20 0.52
▸ FLT1 P17948 1/20 0.52
▸ LTK P29376 1/20 0.52
▸ GRK5 P34947 1/20 0.52
▸ KDR P35968 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29431169 1.00 PRKCI (1.00) PRKCIAXLIKBKBCHUKAURKB
Tert-Butyl Formate SCHEMBL27870995 0.81 PRKCI (0.66) PRKCIAXLIKBKBCHUKAURKB
Ethoxycarbonyl Group SCHEMBL28129959 0.80 PRKCI (0.64) PRKCIAXLIKBKBCHUKAURKB
SCHEMBL2240671 0.77 AURKB (0.71) PRKCIAXLIKBKBCHUKAURKB
SCHEMBL3339974 0.74 PRKCI (0.59) PRKCIAXLIKBKBCHUKAURKB
SCHEMBL91443 0.74 PRKCI (0.59) PRKCIAXLIKBKBCHUKAURKB
SCHEMBL306661 0.74 PRKCI (0.59) PRKCIAXLIKBKBCHUKAURKB
SCHEMBL1176829 0.74 PRKCI (0.59) PRKCIAXLIKBKBCHUKAURKB
SCHEMBL21062776 0.74 PRKCI (0.59) PRKCIAXLIKBKBCHUKAURKB
SCHEMBL30991796 0.74 PRKCI (0.59) PRKCIAXLIKBKBCHUKAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1087 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117903130-A Synthesis method of 4-hydroxy-7-azaindole 苏州艾缇克药物化学有限公司 2024-04-19 — — CN claimed
CN-116554170-A Preparation method of 4-fluoro-7-azaindole 上海大学 2023-08-08 — — CN claimed
CN-102101870-B Synthesis method of azaindole borate compounds ZHOU YULIAN 2012-10-10 — — CN claimed
CN-102101870-A Synthesis method of azaindole borate compounds ZHANGJIAGANG TIANYOU NEW MATERIAL TECHNOLOGY CO LTD 2011-06-22 — — CN claimed
EP-4027995-B1 HPK1 ANTAGONISTS AND USES THEREOF NIMBUS SATURN INC (US) 2026-05-27 — — EP disclosed
EP-4747250-A1 KINASE INHIBITORS The United States Of America, As Represented By The Secretary, Department of Health and Human Services (US) 2026-05-27 — — EP disclosed
US-12583856-B2 Inhibitors of protein kinase A BLUEPRINT MEDICINES CORPORATION (US) 2026-03-24 — — US disclosed
US-20260078119-A1 DEGRADER COMPOUNDS AND USES THEREOF BRISTOL MYERS SQUIBB CO (US) 2026-03-19 — — US disclosed
US-12577231-B2 Androgen receptor PROTACS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2026-03-17 — — US disclosed
US-12544382-B2 2, 4, 6-tri-substituted pyrimidine compound as ATR kinase inhibitor BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) 2026-02-10 — — US disclosed
US-20260035373-A1 PYRROLOPYRIMIDINE ITK INHIBITORS ACLARIS THERAPEUTICS INC (US) 2026-02-05 — — US disclosed
US-20260001865-A1 ANDROGEN RECEPTOR PROTACS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2026-01-01 — — US disclosed
WO-2006124863-A2 PYRROLOPYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2006-11-23 — — WO disclosed
US-20060058304-A1 Azaindole kinase inhibitors BHIDE RAJEEV S 2006-03-16 — — US disclosed
US-6969717-B2 Azaindole kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2005-11-29 — — US disclosed
CN-1681818-A Azaindole kinase inhibitors BRISTOL MYERS SQUIBB CO (US) 2005-10-12 — — CN disclosed
EP-1539763-A1 AZAINDOLE KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2005-06-15 — — EP disclosed
US-20040063707-A1 Azaindole kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2004-04-01 — — US disclosed
WO-2004009601-A1 AZAINDOLE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-01-29 — — WO disclosed
WO-2003000690-A1 SYNTHESIS OF HETEROCYCLIC COMPOUNDS EMPLOYING MICROWAVE TECHNOLOGY AVENTIS PHARMACEUTICALS INC. (US) 2003-01-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260035373-A1 PYRROLOPYRIMIDINE ITK INHIBITORS JAK3, JAK1, JAK2 PRKCI 995/4885AXL 1140/4885IKBKB 171/4885
US-20260078119-A1 DEGRADER COMPOUNDS AND USES THEREOF CTTN, SRC, PTK2 PRKCI 1106/4885AXL 260/4885IKBKB 2608/4885
US-20260001865-A1 ANDROGEN RECEPTOR PROTACS AR, CRBN, PSMA3 PRKCI 2104/4885AXL 2754/4885IKBKB 2780/4885
US-20040063707-A1 Azaindole kinase inhibitors FGFR1, FGFR2, FLT1 PRKCI 757/4885AXL 103/4885IKBKB 1152/4885
US-12583856-B2 Inhibitors of protein kinase A CSNK1A1, CSNK1A1L, CSNK1G1 PRKCI 17/4885AXL 699/4885IKBKB 525/4885
US-12577231-B2 Androgen receptor PROTACS AR, CRBN, PSMA3 PRKCI 2104/4885AXL 2754/4885IKBKB 2780/4885
US-12544382-B2 2, 4, 6-tri-substituted pyrimidine compound as ATR kinase inhibitor ATR, CHEK1, CHEK2 PRKCI 252/4885AXL 408/4885IKBKB 1115/4885
US-20060058304-A1 Azaindole kinase inhibitors FGFR1, FGFR2, FLT1 PRKCI 754/4885AXL 82/4885IKBKB 1216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.